Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics Market by Disease, by Drug Class, by Distribution Channel, and by Region" report has been added to ResearchAndMarkets ...
The European Medicines Agency (EMA) on Tuesday published an analysis highlighting the complexity of developing treatments for central nervous system (CNS) disorders, such as Alzheimer's disease, ...
Adults 65 and older with cognitive disorders such as dementia are more likely to suffer negative effects from drugs that ...
Nanoparticle-mediated delivery has emerged as a transformative approach to transport therapeutic agents across the blood–brain barrier (BBB) and into the central nervous system (CNS). These systems, ...
Intra-arterial drug delivery (IADD) represents a targeted therapeutic approach in which anticancer agents are administered directly into the arteries supplying central nervous system (CNS) tumours. By ...
Six states will require medical proof for Medicaid work exemptions in January, skipping a federal grace year. Who is affected and what to gather. MedPAC Chair Defends $76 Billion Medicare Advantage ...
An experimental drug reversed vision loss and paralysis in mice with MS-like symptoms, prompting researchers to explore its ...
Migraine treatment took a leap forward with CGRP inhibitors, a drug class that has progressed from novel medicines to first-line therapies over the past decade. But there’s still an unmet need for ...
Superstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter. The quarter-end position value was $6.84 million, representing a new holding in Axsome Therapeutics ...
Hosted on MSN
Key FDA drugs advisory committee to be reconstituted
The US FDA's Peripheral and Central Nervous System Drugs Advisory Committee has been terminated and will be re-established, according to a notice in the Federal Register. The notice states that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results